Antiangiogenic drugs and advanced proliferative diabetic retinopathy

Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied.

Saved in:
Bibliographic Details
Main Authors: Ribeiro,Jefferson Augusto Santana, Messias,André, Jorge,Rodrigo
Format: Digital revista
Language:English
Published: Conselho Brasileiro de Oftalmologia 2011
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-27492011000200017
record_format ojs
spelling oai:scielo:S0004-274920110002000172011-07-11Antiangiogenic drugs and advanced proliferative diabetic retinopathyRibeiro,Jefferson Augusto SantanaMessias,AndréJorge,Rodrigo Anti-angiogenic drugs Vitrectomy Diabetic retinopathy Retinal detachment Vitreous hemorrhage Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied.info:eu-repo/semantics/openAccessConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia v.74 n.2 20112011-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017en10.1590/S0004-27492011000200017
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Ribeiro,Jefferson Augusto Santana
Messias,André
Jorge,Rodrigo
spellingShingle Ribeiro,Jefferson Augusto Santana
Messias,André
Jorge,Rodrigo
Antiangiogenic drugs and advanced proliferative diabetic retinopathy
author_facet Ribeiro,Jefferson Augusto Santana
Messias,André
Jorge,Rodrigo
author_sort Ribeiro,Jefferson Augusto Santana
title Antiangiogenic drugs and advanced proliferative diabetic retinopathy
title_short Antiangiogenic drugs and advanced proliferative diabetic retinopathy
title_full Antiangiogenic drugs and advanced proliferative diabetic retinopathy
title_fullStr Antiangiogenic drugs and advanced proliferative diabetic retinopathy
title_full_unstemmed Antiangiogenic drugs and advanced proliferative diabetic retinopathy
title_sort antiangiogenic drugs and advanced proliferative diabetic retinopathy
description Advanced diabetic retinopathy with tractional retinal detachment or persistent vitreous hemorrhage often requires surgical treatment with pars plana vitrectomy. Despite advances in vitrectomy, surgery for complications of diabetic retinopathy can be a challenge and may be impaired by intense fibrovascular proliferation. Antiangiogenic drugs have been used for the treatment of diabetic retinopathy because of their inhibitory action on vascular endothelial growth factor. In this review, we discuss aspects related to the adjuvant use of these drugs in vitrectomy for complications of diabetic retinopathy. Bevacizumab shows beneficial effects regarding the surgical technique facilitation, but its long-term benefit still needs to be studied.
publisher Conselho Brasileiro de Oftalmologia
publishDate 2011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492011000200017
work_keys_str_mv AT ribeirojeffersonaugustosantana antiangiogenicdrugsandadvancedproliferativediabeticretinopathy
AT messiasandre antiangiogenicdrugsandadvancedproliferativediabeticretinopathy
AT jorgerodrigo antiangiogenicdrugsandadvancedproliferativediabeticretinopathy
_version_ 1756373142840803328